ImmunAdd Inc.

Booth 843
Taipei City, Taiwan
Founded in 2021, ImmunAdd, Inc., is a privately held biopharmaceutical company on a mission to improve health through advances in adjuvant design and formulation.
We are developing next-generation saponin adjuvants and using them as the basis for new combination adjuvants and adjuvanted vaccines.
Our lead adjuvant, IA-05, is a rationally designed analog of the saponin adjuvant QS-21. IA-05 elicits immune responses comparable to or better than QS-21 and is better tolerated and more stable.
With IA-05 as the foundation, ImmunAdd is designing adjuvant platforms able to deliver a specific immune response .